Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TEX30 encodes a protein whose detailed biological function is not yet elucidated in humans. It contains an alpha/beta hydrolase-like domain, suggesting putative enzymatic activity, though direct biochemical function remains undetermined. Disease associations include links to rectal adenoma and spermatogenic failure 25, but no robust mechanistic or therapeutic relevance has been established. The gene is highly expressed in testis and is one of many testis-expressed genes possibly relevant to reproduction based on conserved protein domains. There is no current evidence for direct drug targeting, biomarker use, or established safety concerns in clinical contexts. Essentially, TEX30 is a poorly characterized, testis-expressed protein with potential relevance to male fertility, but without sufficient data for detailed molecular or therapeutic classification
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Testis-expressed protein 30 (TEX30).